Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient.
We report on a patient with a transplanted kidney and metastatic testicular cancer who received 4 cycles of cisplatin and etoposide. The patient experienced no renal toxicity and was free of disease after 5 years. Patient management issues are discussed.
Vogelzang
N J
NJ
Section of Hematology/Oncology, University of Chicago, Illinois.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007668:Kidney / Q000187:drug effects; D016030:Kidney Transplantation; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D002945:Cisplatin